
NextGen Group, which does business as NextGen Sciences, puts proteins to the test. The research and development company provides protein analysis services for biotechnology and pharmaceutical customers around the world. Specific services include biomarker discovery and assay development, which are often used in the drug development process to test preclinical and clinical samples for therapeutic efficacy and safety. NextGen's biomarker projects focus on Alzheimer's disease and oncology, among other therapeutic areas. The group has operations in the US and the UK.

Response Genetics Inc. company was founded in 1999 and is headquartered in Los Angeles, California. Response Genetics, Inc., a life sciences company, engages in the research, development, marketing, and sale of clinical diagnostics and pharmacogenomic tests for use in the treatment of cancer in the United States, Europe, and Japan. It offers ResponseDX: Lung test suite, which comprises KRAS Mutation and EGFR Amplification tests. The KRAS Mutation test identifies tumors that have low probability of response to EGFR-directed therapy. The EGFR Amplification test assesses the probability of benefit from EGFR-directed therapy. The company also offers ResponseDX: Colon test suite that includes ERCC1, KRAS Mutation, and TS tests. The ERCC1 test is a test for the probability of response to platin-based therapies and the analysis of RRM1 tests for the probability of response to gemcitabine-based therapies. The TS test measures the probability of response to 5-fluorouracil -based chemotherapy. In addition, Response Genetics, Inc. is developing tests of other types of cancer that identify genetic profiles of tumors that recur after surgery. The company has collaboration agreements with Shanghai BioChip Company, Ltd. to provide pharmacogenomic testing services in China using the company's RGI-1 extraction technology; and Hitachi Chemical Co., Ltd. to use its techniques to extract genetic information from formalin-fixed paraffin-embedded tissue samples. It offers its services in the areas of oncology for oncologists, hospitals, and physician offices through the sales force.

Omrix Biopharmaceuticals helps keep blood in its place in the operating room. The company develops biosealants derived from human plasma to control bleeding during surgical procedures. The biosealants contain naturally occurring proteins that clot and adhere to tissue. Johnson & Johnson's Ethicon subsidiary markets and distributes these products under the names Evicel in the US and Quixil in Europe. Omrix's Evithrom thrombin product was developed with Ethicon primarily for neurosurgery. The FDA has approved both for hemostasis (minimizing blood loss) during surgery. Omrix was acquired by Johnson & Johnson in 2008 and became part of the Ethicon division.

Goldshield Group plc, through its subsidiaries, engages in the development, marketing, and distribution of pharmaceutical and consumer health products. It offers ethical pharmaceuticals, non-prescription medicines, vitamins, minerals and supplements, and various other healthcare products. The company’s pharmaceutical products comprise Ostex, a glucosamine sulphate for joints; Flexeze for glucosamine; and Flexeze Truefil capsules for joints and connective tissues. Its pharmaceutical products are used for chronic disease areas, including cardiovascular diseases, central nervous system disorders, and musculoskeletal conditions. The company’s consumer health products include Appesat for natural weight loss; LIPObind, a natural weight management supplement; Lubramine, a supplement for joint health; Kamillosan, a breastfeeding product; and Infaderm, a soap-free bubble bath product. Its consumer health products also include joints and mobility, bone health, antioxidants, heart and circulation, digestion and detox, weight management, men’s health, women's health, skin care and beauty, heart and bone health, fitness nutrition, immune boosters, joint health, cardiac health, multi vitamins, pet health, centural specials, anti aging, eye health, and well being products. In addition, the company develops wellbeing villages and resorts; publishes magazines for consumers, as well as sells subscriptions and advertising space; and provides telemarketing and management services. Goldshield Group operates in the United Kingdom, Ireland, North America, and India. The company was founded in 1991 and is headquartered in Croydon, the United Kingdom. As of December 21, 2009, Goldshield Group plc was taken private.

Dendreon Corporation, formerly known as Activated Cell Therapy, Inc., was founded in 1992 and is headquartered in Seattle, Washington. Dendreon Corporation (Dendreon) is a biotechnology company focused on the discovery, development and commercialization of therapeutics that improve cancer treatment options for patients. Dendreon’s most advanced product candidate is Provenge (sipuleucel-T), an active cellular immunotherapy that has completed two Phase III trials for the treatment of asymptomatic, metastatic, androgen-independent prostate cancer.

Oxford Gene Technology Ltd. owned company was founded in 1995 by Professor Sir Edwin Southern. Oxford Gene Technology (OGT) provides microarray products and services that enable clinical research and molecular diagnostics in academic, hospital, and government research laboratories. One of its key business areas, licensing, gives companies access to its intellectual property that covers microarrays, genomics, and electrochemistry. OGT's research focuses on developing novel microarray technologies for new applications such as drug discovery and disease diagnosis.

Bilcare was founded in 1995 by chairman Mohan Bhandri. Billing consumers is one of the few things that Bilcare doesn't care about when it comes to pharmaceuticals. The company is a full-service pharmaceutical development company whose services include discovery and research, clinical trial supplies manufacturing and distribution, and clinical trials management. The company also develops and manufactures prescription pharmaceuticals packaging and packaging machines. Research and manufacturing facilities are in operation in India, Singapore, the UK, and the US; additional international offices are scattered around some 30 countries worldwide. Clients include GlaxoSmithKline, Johnson & Johnson, and Pfizer.

MediGene develops drugs that save lives or just make life easier. Spun off from the Munich Gene Center in 1994, MediGene focuses its R&D efforts on therapies that battle various forms of cancer and autoimmune conditions. It also has several drugs on the market, many of them sold through partnerships with other drug firms. The company's Eligard treatment for prostate cancer is sold in Europe by Astellas Pharma, and its Veregen ointment for genital warts is on the US market (Bradley Pharmaceuticals (now part of Nycomed US) sells the drug). In 2008 MediGene won approval from European regulatory authorities for Oracea, a treatment for rosacea; it sold European marketing rights for the drug to Galderma Laboratories.

Amicus Therapeutics, Inc. company was founded in 2002 and is based in Cranbury, New Jersey. Amicus Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of orally administered, small molecule drugs, known as pharmacological chaperones, for the treatment of a range of human genetic diseases. The Company’s products in development are Amigal (migalastat hydrochloride) for Fabry disease, Plicera (isofagomine tartrate) for Gaucher disease and AT2220 (1-deoxynojirimycin HCl) for Pompe disease. The Company completed its Phase II clinical trials of Amigal and are conducting Phase II clinical trials of Plicera and AT2220.

GlaxoSmithKline Biologicals s.a. company was founded in 1945 and is based in Rixensart, Belgium. Glaxosmithkline Biologicals S.A. operates as a subsidiary of GlaxoSmithKline plc. Glaxosmithkline Biologicals S.A. engages in the research, development, manufacture, and supply of vaccines. Its vaccination products are used to tackle various diseases, such as rabies, diphtheria, tetanus, and yellow fever, as well as polio, measles, mumps, and rubella and hepatitis B. Glaxosmithkline Biologicals S.A. was formerly known as SmithKline Beecham Biologicals S.A. and changed its name to GlaxoSmithKline Biologicals S.A. in 2000.
Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.







.webp)
.webp)
.webp)
.webp)
.webp)







